IP Library Granted Patent US 11,261,231
Granted Patent B2
US 11,261,231 · App. 15/208,924 · Granted Mar 1, 2022

Methods for inhibiting HIV or HCV infection by administering TIM-3 binding inhibitors

Inventors: Richard B. Jones (Toronto, CA); Mario Ostrowski (Toronto, CA); Douglas F. Nixon (San Francisco, CA); Lishomwa C. Ndhlovu (San Francisco, CA); James Rini (New York, CA)
Assignees: Altor BioScience, LLC.; The Regents of the University of Califoria
C07K14/70503C07K16/2803G01N33/6863G01N33/6866C07K16/1009C12N2740/16011C12N2770/24211G01N33/56988G01N33/576G01N2333/525G01N2333/57G01N2800/52G01N2800/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,231
App. No.
15/208,924
Granted
Mar 1, 2022
Kind
B2
Abstract

The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.

Claims (7)

1. A method for inhibiting a viral infection in a subject in need thereof comprising administering an effective amount of an inhibitor of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3), wherein the inhibitor is a means for binding Tim-3, and wherein the viral infection is a human immunodeficiency virus (HIV) infection or a hepatitis C virus (HCV) infection, and wherein the Tim-3 to which the inhibitor binds has at least 90% sequence identity to SEQ ID NO: 2 or 6.

2. The method of claim 1 , wherein the viral infection is a chronic viral infection.

3. The method of claim 1 , further comprising administering an effective amount of an antigen expressed by a virus that causes a chronic infection.

4. The method of claim 3 , wherein the chronic virus is human immunodeficiency virus type 1 (HIV-1) or hepatitis C virus (HCV).

5. The method of claim 1 wherein the viral infection is a human immunodeficiency virus (HIV) infection.

6. The method of claim 1 wherein the viral infection is a hepatitis C virus (HCV) infection.

7. The method of claim 1 wherein the means for binding Tim-3 comprises an anti-Tim-3 antibody that specifically binds to an amino acid sequence according to SEQ ID NO: 2 or 6.

Assignments (7)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
MERGER Recorded Nov 11, 2020
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE, LLC
Reel/Frame 054339/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2020
From: JONES, RICHARD BRAD; OSTROWSKI, MARIO; RINI, JAMES
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 054339/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2016
From: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
To: JONES, RICHARD B.; OSTROWSKI, MARIO; RINI, JAMES
Reel/Frame 039218/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2016
From: JONES, RICHARD BRADLEY; OSTROWSKI, MARIO ANTHONY
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 039217/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2016
From: NDHLOVU, LISHOMWA CHAKANGA; NIXON, DOUGLAS F.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 040039/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2016
From: RINI, JAMES
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 039218/0056 →
Continuity (3)
Division 12739639
Provisional Application 60982771 · Oct 26, 2007
Related Publication 20160311890A1 · Oct 27, 2016